Literature DB >> 19636573

Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolecetomy for ulcerative colitis.

Anna Lepistö1, Sari Kivistö, Leena Kivisaari, Johanna Arola, Heikki J Järvinen.   

Abstract

PURPOSE: The prevalence of primary sclerosing cholangitis (PSC) among patients with ulcerative colitis needing proctocolectomy is about 12%. The study aim was to evaluate the progression of the liver disease after surgery.
METHODS: PSC progression in 68 patients with UC after restorative proctocolectomy was evaluated after a median follow-up of 11 years (range 0 to 21). Magnetic resonance imaging (MRI) of the liver, histological examination of a core needle liver specimen, and liver function tests were used in addition to clinical history.
RESULTS: Of the 68 patients, 30 participated in follow-up examinations. Ductal changes in MRI suggesting a diagnosis of PSC occurred in 21 (72%) of them. One carcinoma of the gallbladder was found in MRI. Histopathologic changes suggesting PSC were observable in 15 (50%) patients. Compared to stage in peroperative biopsies taken at proctocolectomy, PSC stage increased in four (13%) patients, decreased in 15 (50%), and remained unchanged in 11 (37%). Immunohistochemical staining for cytoceratin-7 in hepatocytes was positive in nine (30%) indicating cholestasis. After IPAA surgery, five patients underwent liver transplantation at 1, 1, 5, 6, and 11 years, respectively. Of the 68, six patients have, to date, developed cholangiocarcinoma.
CONCLUSIONS: Progression of PSC in patients with minor ductal changes at the time of restorative proctocolectomy is unlikely. Those patients with more advanced disease at surgery are at risk for disease progression and liver transplantation. We lack accurate diagnostic methods to detect premalignant changes of the biliary epithelium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19636573     DOI: 10.1007/s00384-009-0773-4

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  22 in total

Review 1.  Early detection and treatment of cholangiocarcinoma.

Authors:  G J Gores
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

2.  Primary sclerosing cholangitis: a long-term follow-up study.

Authors:  E Aadland; E Schrumpf; O Fausa; K Elgjo; A Heilo; T Aakhus; E Gjone
Journal:  Scand J Gastroenterol       Date:  1987-08       Impact factor: 2.423

3.  Serum trypsinogen-2 and trypsin-2-alpha(1)-antitrypsin complex in malignant and benign digestive-tract diseases. Preferential elevation in patients with cholangiocarcinomas.

Authors:  J Hedström; C Haglund; R Haapiainen; U H Stenman
Journal:  Int J Cancer       Date:  1996-05-03       Impact factor: 7.396

4.  Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis.

Authors:  J Ludwig; S S Barham; N F LaRusso; L R Elveback; R H Wiesner; J T McCall
Journal:  Hepatology       Date:  1981 Nov-Dec       Impact factor: 17.425

Review 5.  Primary sclerosing cholangitis and cholangiocarcinoma as a diagnostic and therapeutic dilemma.

Authors:  D J van Leeuwen; J W Reeders
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

6.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

7.  Sclerosing cholangitis.

Authors:  George R MacFaul; Roger W Chapman
Journal:  Curr Opin Gastroenterol       Date:  2004-05       Impact factor: 3.287

8.  Interlobular bile duct loss in pediatric cholestatic disease is associated with aberrant cytokeratin 7 expression by hepatocytes.

Authors:  Linda M Ernst; Nancy B Spinner; David A Piccoli; Joanne Mauger; Pierre Russo
Journal:  Pediatr Dev Pathol       Date:  2007 Sep-Oct

9.  Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients.

Authors:  J H Helzberg; J M Petersen; J L Boyer
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

10.  Liver involvement and its course in patients operated on for ulcerative colitis.

Authors:  K Mikkola; T Kiviluoto; M Riihelä; M Taavitsainen; H J Järvinen
Journal:  Hepatogastroenterology       Date:  1995-02
View more
  6 in total

1.  Primary sclerosing cholangitis and extraintestinal manifestations in patients with ulcerative colitis and ileal pouch-anal anastomosis.

Authors:  Hans H Wasmuth; Gerd Tranø; Birger H Endreseth; Arne Wibe; Astrid Rydning; Helge E Myrvold
Journal:  J Gastrointest Surg       Date:  2010-05-18       Impact factor: 3.452

2.  Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy.

Authors:  Sombat Treeprasertsuk; Einar Björnsson; Emmanouil Sinakos; Emma Weeding; Keith D Lindor
Journal:  World J Gastrointest Pharmacol Ther       Date:  2013-08-06

Review 3.  Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk.

Authors:  Udayakumar Navaneethan
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-06-20

Review 4.  Does colectomy affect the progression of primary sclerosing cholangitis? A systematic review and meta-analysis.

Authors:  John Ong; Michael F Bath; Carla Swift; Yasseen Al-Naeeb
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2018

5.  Circulating CD4+CD25+ regulatory T cells in the pathobiology of ulcerative colitis and concurrent primary sclerosing cholangitis.

Authors:  Murat Kekilli; Bilge Tunc; Yavuz Beyazit; Mevlut Kurt; Ibrahim Koral Onal; Aysel Ulker; Ibrahim Celalettin Haznedaroglu
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

6.  Keratin 7 expression in hepatic cholestatic diseases.

Authors:  S Sakellariou; C Michaelides; T Voulgaris; J Vlachogiannakos; E Manesis; D G Tiniakos; I Delladetsima
Journal:  Virchows Arch       Date:  2021-07-27       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.